ArticleiScience2022
The origin of bladder cancer from mucosal field effects.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- Human Y chromosome pan-organ mapping reveals progressive mosaic loss from normal to cancer.JCI insight · 2026Article
- Urinary Biomarkers in Urological Oncology: From Biological Origin to Clinical Decision-Making-A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- [Impact of coexistent low-grade components on the prognosis of high-grade non-muscle invasive bladder cancer].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.Cancer science · 2026Article
- Article
- A comparative study of statistical methods for identifying differentially expressed genes in spatial transcriptomics.PLoS computational biology · 2026Article
- Mechanisms and implications of epithelial cell plasticity in the bladder.Nature reviews. Urology · 2026Review
- HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothened.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Field cancerization in urothelial carcinoma: molecular alterations and clinical implications.Journal of Cancer · 2026Review
- Dysregulated mitochondrial energy metabolism drives the progression of mucosal field effects to invasive bladder cancer.The Journal of pathology · 2025Article
- What spatial omics is teaching us about field cancerisation in prostate and bladder cancer.BJU international · 2025Review
- Modeling and validation of serum miR-18a and miR-122 levels as predictors of recurrence after laparoscopic radical cystectomy procedure for bladder cancer based on nomogram model.Frontiers in oncology · 2025Article
- Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.Translational cancer research · 2024Review
- Imposter among us: field cancerization in the bladder.Translational andrology and urology · 2024Article
- Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis.Cell reports · 2024Article
- Inferring Bladder Cancer Evolution from Mucosal field Effects by Whole-Organ Spatial Mutational, Proteomic, and Metabolomic Mapping.Research square · 2024Article
- The urothelial gene regulatory network: understanding biology to improve bladder cancer management.Oncogene · 2024Review
- MRI/RNA-Seq-Based Radiogenomics and Artificial Intelligence for More Accurate Staging of Muscle-Invasive Bladder Cancer.International journal of molecular sciences · 2023Article
- Bladder cancer.Nature reviews. Disease primers · 2023Review
- Review
Corrections and comments
- Erratum issued
Authors and funding
26 authors at 7 institutions in 2 countries.
Jolanta BondarukDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Roman JaksikDepartment of Systems Biology and Engineering and Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.
Ziqiao WangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David CogdellDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sangkyou LeeDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yujie ChenSystems, Synthetic and Physical Biology Program, Rice University, Houston, TX, USA.
Khanh Ngoc DinhDepartment of Statistics and the Irving Institute for Cancer Dynamics, Columbia University, New York, NY, USA.
Tadeusz MajewskiDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Li ZhangDepartment of Environmental Health, University of Cincinnati, Cincinnati, OH, USA.
Shaolong CaoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Feng TianDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hui YaoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paweł KuśDepartment of Systems Biology and Engineering and Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.
Huiqin ChenDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John N WeinsteinDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neema NavaiDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Colin DinneyDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianjun GaoDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, TX, USA.
Dan TheodorescuSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, Los Angeles, CA, USA.
Christopher LogothetisDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, TX, USA.
Charles C GuoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wenyi WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David McConkeyJohns Hopkins Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD, USA.
Peng WeiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Marek KimmelDepartment of Statistics, Rice University, Houston, TX, USA.
Bogdan CzerniakDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USRice University · USSilesian University of Technology · PLCedars-Sinai Medical Center · USColumbia University · USJohns Hopkins University · USUniversity of Cincinnati · US
Funding
Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4MStatistical methods for genomic analysis of heterogeneous tumorsR01CA268380 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Wenyi Wang · 2022 to 2026
$2.4MThe Contribution ofInfection to Preleukemic Clonal HematopoiesisR01HL136333 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI KING, KATHERINE YUDEH · 2017 to 2020
$1.9MStatistical methods for genomic analysis of heterogeneous tumorsR01CA183793 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, WENYI · 2014 to 2018
$1.7MInflammatory Regulation of Hematopoietic Stem and Progenitor Cells to Enhance Innate ImmunityR01HL134880 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI KING, KATHERINE YUDEH · 2017 to 2020
$1.6MNCI NIH HHS P50 CA091846NCI NIH HHS R01 CA183793NCI NIH HHS R01 CA268380NHLBI NIH HHS R01 HL134880NHLBI NIH HHS R01 HL136333
Abstract
Whole-organ mapping was used to study molecular changes in the evolution of bladder cancer from field effects. We identified more than 100 dysregulated pathways, involving immunity, differentiation, and transformation, as initiators of carcinogenesis. Dysregulation of interleukins signified the involvement of inflammation in the incipient phases of the process. An aberrant methylation/expression of multiple
Indexed as
CancerCell biologyMolecular biology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.